Skip to main content
. 2018 Sep 26;10:1349–1358. doi: 10.2147/CLEP.S175063

Figure 1.

Figure 1

Cumulative incidence of bone-modifying agent initiation (A), interruption, and reinitiation (B) among patients with bone metastasis from breast cancer in the US, 2013–2016.

Abbreviation: BMA, bone-modifying agent.